¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31
±³À°ÀÏÀÚ : 2024-05-31
±³À°Àå¼Ò : ¼­¿ï¾Æ»êº´¿ø ¿¬±¸°ü

±³À°ÁÖÁ¦ : 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 60¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í ºñȸ¿ø 50,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 13:30~14:00 Clinical significance of BRAFV600E-positive cells as measurable residual disease (MRD) in Langerhans cell histiocytosi Ko Kudo(Hirosaki University, Japan)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 14:00~14:30 How we treat LCH(Langerhans cell histiocytosis) in Taiwan Grace Yu Mei Liao(Medical University, Taiwan)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 14:30~15:00 Unraveling the Genetic Tapestry of Langerhans Cell Histiocytosis in Korean Patients °í°æ³²(¿ï»êÀÇ´ë)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 15:15~15:45 Stratified treatment of pediatric HLH(Hemophagocytic lymphohistiocytosis) Rui Zhang(Capital  Medical University, China)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 15:45~16:15 Primary and secondary hemophagocytic lymphohistiocytosis in Japan Shouichi Ohga(Kyushu University, Japan)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 16:15~16:45 HLH(Hemophagocytic lymphohistiocytosis) in Korea ÃÖÁ¤À±(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 17:00~17:30 CAR-T related CSS & cytopenia Yoshiyuki Takahashi(Nagoya University, Japan)

±³À°½Ã°£ 05¿ù 31ÀÏ °­ÀǽÇ1 17:30~18:00 CAR-T related HLH(Hemophagocytic lymphohistiocytosis) À¯Àç¿ø(°¡Å縯ÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÀ忬±¸ÇÐȸ ºÎ¿ï°æÁöȸ Á¤±âÁý´ãȸ : 2024-04-29
´ÙÀ½±Û ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
1217 ¼­¿ï 2018 ´ëÇѺñ´¢±â°úÇÐȸ Á¦70Â÷ Ãß°èÇмú´ëȸ : 2018-11-30 0 2,619 2018-09-28
1216 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú Áö¿ªÀÇ»ç Áý´ãȸ : 2018-11-29 0 508 2018-09-28
1215 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø À̺ñÀÎÈÄ°ú 2Çбâ Áö¿ªÀÇ»çÁý´ãȸ(±â¸³¼º ¾îÁö·³Áõ) : 2018-11-29 0 762 2018-09-28
1214 ¼­¿ï 2018 ´ëÇѺñ´¢±â°úÇÐȸ Á¦70Â÷ Ãß°èÇмú´ëȸ : 2018-11-29 0 1,128 2018-09-28
1213 ´ëÀü °¡Å縯´ëÇб³´ëÀü¼º¸ðº´¿ø Á¦6ȸ °³¿øÀǸ¦ À§ÇÑ ½ÉÀüµµ ±³À° ½ÉÆ÷Áö¾ö : 2018-11-28 0 2,173 2018-09-28
1212 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø ¼ÛÆı¸(5Â÷) °³¿øÀÇ ¿¬¼ö±³À°(¼Òº¯¹®Á¦, °í¿ä»êÇ÷Áõ) : 2018-11-27 0 1,240 2018-09-28
1211 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø ¾È°ú Áö¿ªÀÇ»ç Áý´ãȸ(¸Á¸·Áúȯ) : 2018-11-27 0 1,016 2018-09-28
1210 °æ±â Â÷ÀÇ°úÇдëÇб³ºÐ´çÂ÷º´¿ø °¢¸· ¹× Àü¾ÈºÎ : 2018-11-27 0 785 2018-09-28
1209 ¼­¿ï ÀÌÈ­¿©ÀÚ´ëÇб³ÀÇ´ëºÎ¼Ó¸ñµ¿º´¿ø ÀÎÈÄ°ú Áö¿ªÀÇ»ç Áý´ãȸ : 2018-11-27 0 582 2018-09-28
1208 ¼­¿ï »ï¼º¼­¿ïº´¿ø ´ëÇÑÀÌ°úÇÐȸ 2018 ÀÌ°úÇÐ Live Surgery ¹× ½ÅÀÇ·á±â¼ú ¼¼¹Ì³ª : 2018-11-25 0 671 2018-09-28
1207 ÀÎõ 2018 °¡Ãµ´ë ±æº´¿ø Facial Surgery Symposium : 2018-11-25 0 1,171 2018-09-28
1206 ¼­¿ï ´ëÇÑ°©»ó¼±³»ºÐºñ¿Ü°úÇÐȸ Ãß°è½ÉÆ÷Áö¾ö : 2018-11-25 0 1,289 2018-09-28
1205 ¼­¿ï »ï¼º¼­¿ïº´¿ø ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ ȸÀü±Ù°³ ÆÄ¿­/¿ªÇ༺ Àΰø °ß°üÀý ġȯ¼ú/°ß¡¤ÁÖ°üÀý °ñÀý : 2018-11-24 0 2,476 2018-09-28
1204 ¼­¿ï 2018 ´ëÇѼöºÎ¿Ü°úÇÐȸ Cadaver Workshop : 2018-11-24 0 1,048 2018-09-28
1203 ºÎ»ê ´ëÇѽÅÀåÇÐȸ Clinical unmet need; Antibody-mediated rejection : 2018-11-24 0 309 2018-09-28
1331 | 1332 | 1333 | 1334 | 1335 | 1336 | 1337 | 1338 | 1339 | 1340
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷